Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002029280 | SCV002303963 | likely pathogenic | Primary pulmonary hypertension | 2020-11-11 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys496 amino acid residue in BMPR2. Other variant(s) that disrupt this residue have been observed in individuals with BMPR2-related conditions (PMID: 29743074, 16429395), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BMPR2 protein function. This variant has been observed in individual(s) with clinical features of pulmonary arterial hypertension (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces cysteine with tryptophan at codon 496 of the BMPR2 protein (p.Cys496Trp). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tryptophan. |